Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Atezolizumab and Bevacizumab with Chemotherapy in Extended-disease SCLC
NCT04730999Phase 2Completed
- Sponsor
- Gruppo Oncologico Italiano di Ricerca Clinica
- Start
- Jul 2020
- Primary completion
- Jun 2023
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of bevacizumab in small cell lung cancer (SCLC), sponsored by Gruppo Oncologico Italiano di Ricerca Clinica. Started Jul 2020; status: completed.
02
Drugs
bevacizumab
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on NCT04730999.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04730999.